Table 3.
SSc case group (n) | HLA / heterodimer | OR (95% CI) | P value |
AA AFA+ SSc vs. controls | DRA1*01:01/DRB1*08:04 | 7.4 (4.9-11.3) | 2.6 × 10−19 |
SSc = 129; control = 946 | DQA1*01:02/DQB1*06:09 | 4.6 (2.6-7.9) | 4.0 × 10−7† |
AA ATA+ SSc vs. controls | DPA1*02:01/DPB1*13:01 | 4.8 (3.2-7.1) | 8.4 × 10−14 |
SSc = 183; control = 946 | DQA1*05:01/DQB1*02:01 | 0.2 (0.1-0.5) | 5.3 × 10−6† |
DQA1*05:01/DQB1*03:19 | 3.3 (2.0-5.5) | 1.6 × 10−5† | |
EA ATA+ SSc vs. controls | DPA1*02:01/DPB1*13:01 | 15.7 (10.1-24.2) | 1.2 × 10−25 |
SSc = 115; control = 5437 | DRA1*01:01/DRB1*11:04 | 6.4 (3.9-10.4) | 2.9 × 10−11† |
EA ACA+ SSc vs. controls | DRA1*01:01/DRB1*07:01 | 0.1 (0.05-0.2) | 4.8 × 10−20 |
SSc = 239; control = 5,437 | DQA1*01:01/DQB1* 05:01 | 2.0 (1.5-2.6) | 1.8 × 10−6† |
Significance upon conditioning on top associated α/β heterodimer(s).